Literature DB >> 8223841

Development of a population pharmacokinetic database for tianeptine.

T H Grasela1, J B Fiedler-Kelly, C Salvadori, C Marey, R Jochemsen.   

Abstract

Two thousand three hundred and thirty five plasma concentrations of tianeptine from 112 patients enrolled in nine studies of tianeptine pharmacokinetics performed prior to the marketing of the drug were pooled for analysis using mixed-effect modeling. Studies represented a combination of single dose and multiple dosing at steady-state. Tianeptine plasma concentration time data were fit to a two compartment model with first order absorption using the NONMEM computer program. The results of this analysis suggested that alcoholism is associated with significant increase in clearance (124% increase) and volume of the central compartment (161% increase). The volume of the peripheral compartment is significantly lower in women (31% decrease) and in depressed patients (59% decrease). The population mean (interindividual variability) clearance was equal to 0.17 l.h-1 x kg-1 (28.6%), the volume of central compartment was 0.13 l.kg-1 (60.4%), intercompartmental clearance was 0.07 l.h-1 x kg-1 (30.1%), volume of the tissue compartment was 1.17 l.kg-1 (28.3%), and the absorption rate constant was 0.63 h-1 (21.8%). The residual variability was approximately 30% at concentrations expected during clinical use of the drug. Because of the increased clearance, alcoholic patients would be expected to have significantly reduced concentrations during steady-state dosing. These population parameters provide a basis for developing initial dosing recommendations and for performing bayesian evaluations of drug concentrations obtained in post-marketing studies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223841     DOI: 10.1007/bf00315502

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

Authors:  P O Maitre; M Bührer; D Thomson; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

2.  Influence of food on tianeptine and its main metabolite kinetics.

Authors:  A Dresse; J M Rosen; H Brems; H Masset; R Defrance; C Salvadori
Journal:  J Clin Pharmacol       Date:  1988-12       Impact factor: 3.126

3.  Ion-pair extraction and high-performance liquid chromatographic determination of tianeptine and its metabolites in human plasma, urine and tissues.

Authors:  G Nicot; G Lachatre; C Gonnet; J Mallon; E Mocaer
Journal:  J Chromatogr       Date:  1986-08-22

4.  Tianeptine and amitriptyline. Controlled double-blind trial in depressed alcoholic patients.

Authors:  H Lôo; R Malka; R Defrance; D Barrucand; J Y Benard; H Niox-Rivière; A Raab; A Sarda; G Vachonfrance; A Kamoun
Journal:  Neuropsychobiology       Date:  1988       Impact factor: 2.328

5.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

6.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

7.  The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration.

Authors:  C Salvadori; C Ward; R Defrance; R Hopkins
Journal:  Fundam Clin Pharmacol       Date:  1990       Impact factor: 2.748

8.  Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state.

Authors:  S Toon; B L Holt; S J Langley; F G Mullins; M Rowland; M S Halliday; C Salvadori; B Delalleau
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Increased serotonin platelet uptake after tianeptine administration in depressed patients.

Authors:  G Chamba; P Lemoine; E Flachaire; N Ferry; C Quincy; J Sassard; C Ferber; E Mocaër; A Kamoun; B Renaud
Journal:  Biol Psychiatry       Date:  1991-09-15       Impact factor: 13.382

10.  Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis.

Authors:  R J Royer; M J Royer-Morrot; F Paille; D Barrucand; J Schmitt; R Defrance; C Salvadori
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

View more
  5 in total

Review 1.  Tianeptine: a review of its use in depressive disorders.

Authors:  A J Wagstaff; D Ormrod; C M Spencer
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Predictive performance of population pharmacokinetic parameters of tianeptine as applied to plasma concentrations from a post-marketing study.

Authors:  T H Grasela; J B Fiedler-Kelly; C Salvadori; C Marey; R Jochemsen; H Loo
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 3.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

4.  Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics.

Authors:  Britta Haenisch; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-10       Impact factor: 3.000

Review 5.  Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression.

Authors:  M I Wilde; P Benfield
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.